Catalyst Pharma

News

Angelini CEO Sergio Marullo di Condojanni

Angelini seeks US beachhead with $4.1bn Catalyst buy

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

News

Catalyst squares up to FDA over rival drug approval

Catalyst Pharma is suing the FDA over its approval of a potential rival to its rare disease therapy Firdapse, calling it “arbitrary, capricious, and contrary to law.”

Angelini seeks US beachhead with $4.1bn Catalyst buy

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Catalyst squares up to FDA over rival drug approval

Mike Guarino appointed to lead EVERSANA INTOUCH

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks